Haemonetics Stock News

Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.

The "Global Blood Transfusion Devices Market, By Product (Apheresis Systems, Infusion Devices, Blood Warmers, Venous Access Devices, Filters, Others), By Blood Component (Whole Blood, Plasma, RBC, Others), By End User, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com''s offering. The global blood transfusion devices market is expected to grow at a CAGR of around 6% during the forecast period. Companies Mentioned Fresenius Kabi AG Grifols SA Terumo Corporation B Braun Melsungen AG Becton, Dickinson, and Company Immucor Inc Haemonetics Corporation Kaneka Corporation Macopharma SA Tenko International Group Corp The global blood transfusion devices market is driven by upsurge in count of surgical procedures being carried out across the globe. Moreover, developments in terms of technology is expected to positively impact the growth of the market during the forecast period. Also, rise in number of blood related disorders is further expected to bolster the growth of market over the next few years.

Wall Street analysts expect that Haemonetics Co. (NYSE:HAE) will report sales of $266.90 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Haemonetics’ earnings. The highest sales estimate is $274.60 million and the lowest is $256.16 million. Haemonetics reported sales of $240.37 million in the same quarter last […]

Boston Trust Walden Corp lifted its stake in shares of Haemonetics Co. (NYSE:HAE) by 109.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 459,873 shares of the medical instruments suppliers stock after purchasing an additional 240,419 shares during the period. Boston Trust Walden Corp owned []

Oregon Public Employees Retirement Fund trimmed its position in Haemonetics Co. (NYSE:HAE) by 1.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,081 shares of the medical instruments suppliers stock after selling 225 shares during the period. Oregon Public Employees Retirement Funds holdings in Haemonetics []

Tompkins Financial Corp bought a new stake in Haemonetics Co. (NYSE:HAE) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 560 shares of the medical instruments supplier’s stock, valued at approximately $40,000. Other hedge funds and other institutional investors have also […]

Wall Street analysts expect Haemonetics Co. (NYSE:HAE) to announce earnings per share (EPS) of $0.75 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Haemonetics earnings. The lowest EPS estimate is $0.71 and the highest is $0.80. Haemonetics posted earnings of $0.81 per share during the same quarter last []

Assenagon Asset Management S.A. reduced its stake in shares of Haemonetics Co. (NYSE:HAE) by 93.9% in the third quarter, Holdings Channel reports. The fund owned 37,306 shares of the medical instruments suppliers stock after selling 575,474 shares during the quarter. Assenagon Asset Management S.A.s holdings in Haemonetics were worth $2,633,000 as of its most recent []

Cardinal Capital Management lifted its holdings in shares of Haemonetics Co. (NYSE:HAE) by 10.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,828 shares of the medical instruments suppliers stock after acquiring an additional 761 shares during the quarter. Cardinal Capital Managements []

The new study on the Global Blood Cell Separator Market 2021-2027 analyzes the crucial capabilities, key infrastructures, major organizations, evaluates measures to attain potential success in the Blood Cell Separator industry. Because of the in-depth overview of the Global Blood

Goldman Sachs Group Inc. reduced its position in Haemonetics Co. (NYSE:HAE) by 37.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,469 shares of the medical instruments suppliers stock after selling 44,009 shares during the quarter. Goldman Sachs []

Price T Rowe Associates Inc. MD raised its position in Haemonetics Co. (NYSE:HAE) by 0.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 556,314 shares of the medical instruments suppliers stock after purchasing an additional 4,242 shares during the quarter. []

Haemonetics Co. (NYSE:HAE) – Equities research analysts at Barrington Research cut their Q1 2023 earnings per share estimates for Haemonetics in a report released on Wednesday, November 10th. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will post earnings of $0.68 per share for the quarter, down from their prior estimate […]

Haemonetics (HAE) revenues increased year over year in the fiscal second quarter, supported by recovery across major businesses, especially Hospital and the initial Plasma Persona rollouts.

The company broadly meets expectations for its Q2 2022 but trims its full-year guidance.